# Anti-malaria MAb in Kenyan Children

> **NCT05400655** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 912 (actual)

## Conditions studied

- Plasmodium Falciparum Infection
- Malaria

## Interventions

- **DRUG:** L9LS
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05400655
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-14
- **Primary completion:** 2024-06-02
- **Final completion:** 2024-06-02
- **Target enrollment:** 912 (ACTUAL)
- **Last updated:** 2025-10-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05400655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05400655, "Anti-malaria MAb in Kenyan Children". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05400655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*